证券代码：605388 证券简称：均瑶健康 公告编号：2025-039 湖北均瑶大健康饮品股份有限公司 关于 2024 年年度报告的信息披露监管问询函的回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）于近日收 到《上海证券交易所关于湖北均瑶大健康饮品股份有限公司 2024 年年度 报告的信息披露监管问询函》（上证公函【2025】0747 号）（以下简称 "《问询函》"）。根据《问询函》的要求，公司会同中审众环会计师 事务所（特殊普通合伙）年审会计师对《问询函》所列事项逐一复核落 实，现就《问询函》所列事项逐项回复并说明如下： 本回复中若出现总计数尾数与所列数值总和尾数不符的情况，均为 四舍五入所致。如无特别说明，本回复中使用的简称或名词释义与《湖 北均瑶大健康饮品股份有限公司 2024 年年度报告》一致。 鉴于公司回复内容中披露的部分信息涉及商业秘密和商业敏感信息， 根据相关法律法规、规范性文件，对本次《问询函》回复中相关内容进 行豁免披露处理。 依据《公开发行证券的 ...

Group 1 - The company held a shareholders' meeting on June 25, 2025, in Shanghai, with a total attendance representing 70.2642% of the voting shares [1] - The meeting was convened by the board of directors and chaired by Mr. Wang Junhao, utilizing a combination of on-site and online voting methods, complying with relevant laws and regulations [1] - All resolutions presented at the meeting were ordinary resolutions and were approved by more than half of the voting shares held by attending shareholders [2] Group 2 - The legal representatives for the meeting were Lin Hui and Ke Lingfeng, confirming that the meeting's procedures and voting methods were in accordance with the Company Law, Securities Law, and the company's articles of association [2] - The resolutions formed during the meeting were deemed legal and valid [2]

证券代码：605388 证券简称：均瑶健康 公告编号：2025-038 湖北均瑶大健康饮品股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 6 月 25 日 (二)股东大会召开的地点：上海市浦东新区康桥东路 2 弄 1 号楼大会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： (二)涉及重大事项，5%以下股东的表决情况 | 1、出席会议的股东和代理人人数 | 635 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 411,624,749 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 70.2642 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由湖北均瑶大健康饮品股份有限公司（以下简称"公司"）董 事会召集，本次 ...

浩律師(上海)事務所 RANDALL LAW FIRM (SHANGHAI) 昆明 天津 成都 宁波 福州 西安 南京 南 中国上海市静安区山西北路 99 号苏河湾中心 MT 25-28 层 邮编:20008 25-28/F Suhe Centre 99 North Shanxi Road Jing'an District Shang 电话/Tel: +86 21 52341668 传真/Fax: +86 21 523416 网址/Website:http://www.grandall.com.cn 国浩律师(上海)事务所 关于湖北均瑶大健康饮品股份有限公司 2025年第一次临时股东大会的 法律意见书 致:湖北均瑶大健康饮品股份有限公司 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民 共和国证券法》(以下简称"《证券法》")和中国证券监督管理委员会《上市 公司股东会规则》（以下简称"《股东会规则》"）的规定,国浩律师(上海) 事务所接受湖北均瑶大健康饮品股份有限公司(以下简称"公司")董事会的聘 请,指派律师出席了公司于2025年6月25日(星期三)14点00分时起在上海市浦东 新区康桥东 ...

Core Viewpoint - The announcement details the results of share reductions by certain directors and senior management of Hubei Junyao Health Beverage Co., Ltd, indicating a completed share reduction plan with specific amounts and percentages disclosed for each individual involved [1][2]. Summary by Relevant Sections 1. Basic Information on Shareholding - Director Jiang Hailong holds 732,201 shares, accounting for 0.122% of the total share capital - Director Zhu Xiaoming holds 763,218 shares, accounting for 0.127% of the total share capital - Director and Deputy General Manager Luo Xiyue holds 732,269 shares, accounting for 0.122% of the total share capital - Supervisor Chen Yanqiu holds 183,051 shares, accounting for 0.030% of the total share capital - Supervisor Zhu Pengfei holds 183,067 shares, accounting for 0.030% of the total share capital - Deputy General Manager Xiang Weibing holds 368,134 shares, accounting for 0.061% of the total share capital - Financial Officer Cui Peng holds 173,051 shares, accounting for 0.029% of the total share capital - Secretary of the Board Guo Qin holds 441,679 shares, accounting for 0.074% of the total share capital [1][3][4][5][6][8]. 2. Results of the Share Reduction Plan - As of June 20, 2025, Jiang Hailong reduced his holdings by 180,000 shares (0.030%) - Zhu Xiaoming reduced his holdings by 150,000 shares (0.025%) - Luo Xiyue reduced his holdings by 183,000 shares (0.030%) - Financial Officer Cui Peng reduced his holdings by 43,200 shares (0.007%) - Secretary Guo Qin reduced his holdings by 110,000 shares (0.018%) [1][2][9][10]. 3. Details of Share Reduction Transactions - Jiang Hailong's shares were sold at a price range of 7.96 to 8.46 CNY per share, totaling 1,519,900 CNY - Zhu Xiaoming's shares were sold at a price range of 9.00 to 9.72 CNY per share, totaling 1,418,481 CNY - Luo Xiyue's shares were sold at a price of 6.71 CNY per share, totaling 1,227,930 CNY - Financial Officer Cui Peng's shares were sold at a price of 6.71 CNY per share, totaling 289,872 CNY - Secretary Guo Qin's shares were sold at a price of 6.31 CNY per share, totaling 694,199 CNY [9][10].

部分董监高集中竞价减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 董监高持股的基本情况 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）于 2025 年 2 月 28 日在上海证券交易所网站（www.sse.com.cn）披露了《湖北均瑶大健康饮品股份 有限公司部分董监高集中竞价减持股份计划公告》（公告编号：2025-007）。董事 蒋海龙持有公司股份 732,201 股，占公司总股本的比例为 0.122%；董事朱晓明 持有公司股份 763,218 股，占公司总股本的比例为 0.127%；董事兼副总经理罗 喜悦持有公司股份 732,269 股，占公司总股本的比例为 0.122%；监事陈艳秋持 有公司股份 183,051 股，占公司总股本的比例为 0.030%；监事朱鹏飞持有公司 股份 183,067 股，占公司总股本的比例为 0.030%；副总经理向卫兵持有公司股 份 368,134 股，占公司总股本的比例为 0.061%；财务负责人崔鹏持有公司股份 173,051 股，占公司总股 ...

湖北均瑶大健康饮品股份有限公司 二〇二五年第一次临时股东大会会议资料 二〇二五年第一次临时股东大会 会议资料 湖北均瑶大健康饮品股份有限公司 | | | 湖北均瑶大健康饮品股份有限公司 二〇二五年第一次临时股东大会会议资料 会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议 事效率，保证大会的顺利进行，根据中国证监会发布的《上市公司 股东会规则》、《湖北均瑶大健康饮品股份有限公司章程》（以下 简称"《公司章程》"）和《股东大会议事规则》的规定，特制定 本须知，请出席股东大会的全体人员遵照执行： 一、本公司根据《中华人民共和国公司法》、《中华人民共和 国证券法》、《上市公司股东会规则》、《公司章程》及《股东大 会议事规则》的规定，认真做好召开股东大会的各项工作。 二、本公司设立股东大会会务组，具体负责大会有关程序方面 的事宜。 三、本次股东大会以现场会议形式召开。 四、为保证本次大会的严肃性和正常秩序，切实维护股东的合 法权益，务必请出席现场大会的股东（包含股东代表，下同）携带 相关证件，提前到达会场签到。未能提供有效证件办理签到的，不 得参加现场表决和发言。除出席本次会议的公司股东、董事、监事、 ...

Group 1 - The company is holding its first extraordinary general meeting of shareholders in 2025 on June 25, 2025, at 14:00, in Shanghai [4][6] - The meeting will be conducted in a combination of on-site and online voting methods, ensuring participation from shareholders [4][6] - The agenda includes the election of a new independent director to replace the outgoing independent director, with a nomination for Mr. Su Shiyan [4][5][6] Group 2 - Shareholders must present valid identification to participate in the meeting and are required to register in advance [2][3] - The meeting will allow shareholders to exercise their rights to speak, inquire, and vote, while maintaining order and respecting the rights of others [2][3] - The company has engaged a lawyer to witness the meeting and provide a legal opinion [4][6] Group 3 - Mr. Su Shiyan, the independent director candidate, has a background in food science and engineering, with extensive experience in the food and beverage industry [6][7] - His qualifications have been reviewed and approved by the Shanghai Stock Exchange, ensuring compliance with regulatory standards [5][6][7] - The company aims to enhance its board's expertise and governance through this appointment [5][6]

证券代码：605388 证券简称：均瑶健康 公告编号：2025-036 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）股票于 2025 年 6 月 11 日、6 月 12 日、6 月 13 日连续 3 个交易日内收盘价格跌幅偏离值累计超 过 20%。根据《上海证券交易所交易规则》的有关规定，属于股票交易异常波动 情形。 经公司自查及向公司控股股东、实际控制人发函核实、确认，截至本公 告披露日，除公司已披露事项外，不存在其它应披露而未披露的重大事项。 请广大投资者理性投资，注意股票二级市场的交易风险。 一、股票交易异常波动的具体情况 公司股票于 2025 年 6 月 11 日、6 月 12 日、6 月 13 日连续 3 个交易日内收 盘价格跌幅偏离值累计超过 20%。根据《上海证券交易所交易规则》的有关规定， 属于股票交易异常波动情形。 二、公司关注并核实的相关情况 （一）生产经营情况 湖北均瑶大健康饮品股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任 重要内容提示： （四）其他股价敏感信息 ...

Group 1 - The core point of the article highlights that Junyao Health plans to distribute a cash dividend of 0.80 yuan per 10 shares despite reporting a revenue decline of 10.77% and a net loss of 29.12 million yuan, marking the first loss in a decade [1][2] - The total cash dividend to be distributed amounts to 46.87 million yuan, which exceeds the dividend amounts during the previous two profitable years [1] - Approximately 67% of Junyao Health's shares are controlled by the founding family, indicating that around 31.52 million yuan of the dividend will benefit them directly [1] Group 2 - Junyao Health's stock price has seen a significant increase, rising from 6.35 yuan on May 23 to a peak of 12.34 yuan by June 10, nearly doubling in just two weeks [1] - This surge in stock price lacks substantial fundamental support, as the company's core product "Weidongli" has shown weak growth, and new ventures in probiotics have not yet reversed the overall decline [2] - Concerns have arisen regarding potential market speculation due to the lack of clear performance indicators supporting the stock price increase [2] Group 3 - Earlier this year, company executives announced share reductions, raising concerns about the company's future prospects [3] - Junyao Health received a warning from the Hubei Securities Regulatory Bureau for failing to disclose its expected annual loss in a timely manner, leading to criticism from the Shanghai Stock Exchange [3] - The chairman's defense regarding his non-involvement in financial data and disclosure processes highlights potential governance issues within the company [3]